The first double-blind randomized placebo-controlled phase 2 study to assess the efficacy and safety of insulin sensitizer in patients with non-alcoholic steatohepatitis in Asia- an interim report

被引：0
|
作者：
Yeh, Ming-Lun [1 ,2 ]
Huang, Chung-Feng [1 ,2 ,3 ]
Tsai, Pei-Chien [2 ]
Huang, Ching-I [1 ,2 ,3 ]
Dai, Chia-Yen [1 ,2 ,3 ]
Chen, Shinn-Chern [1 ,2 ]
Huang, Jee-Fu [1 ,2 ,3 ,4 ,5 ]
Yu, Ming-Lung [1 ,2 ,4 ,5 ]
Chuang, Wan-Long [1 ,2 ]
机构：
[1] Kaohsiung Med Univ, Fac Internal Med, Coll Med, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ Hosp, Hepatobiliary Div, Dept Internal Med, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ Hosp, Grad Inst Clin Med, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ Hosp, Ctr Liquid Biopsy, Kaohsiung, Taiwan
[5] Kaohsiung Med Univ Hosp, Canc Res Ctr, Kaohsiung, Taiwan
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI101
引用
收藏
页码：S449 / S449
页数：1
相关论文
共 50 条
  • [21] Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
    Navarro, Victor J.
    Belle, Steven H.
    D'Amato, Massimo
    Adfhal, Nezam
    Brunt, Elizabeth M.
    Fried, Michael W.
    Reddy, K. Rajender
    Wahed, Abdus S.
    Harrison, Stephen
    PLOS ONE, 2019, 14 (09):
  • [22] Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
    Harrison, Stephen A.
    Abdelmalek, Manal F.
    Neff, Guy
    Gunn, Nadege
    Guy, Cynthia D.
    Alkhouri, Naim
    Bashir, Mustafa R.
    Freilich, Bradley
    Kohli, Anita
    Khazanchi, Arun
    Sheikh, Muhammad Y.
    Leibowitz, Mark
    Rinella, Mary E.
    Siddiqui, Mohammad S.
    Kipnes, Mark
    Moussa, Sam E.
    Younes, Ziad H.
    Bansal, Meena
    Baum, Seth J.
    Borg, Brian
    Ruane, Peter J.
    Thuluvath, Paul J.
    Gottwald, Mildred
    Khan, Mujib
    Chen, Charles
    Melchor-Khan, Liza
    Chang, William
    DePaoli, Alex M.
    Ling, Lei
    Lieu, Hsiao D.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (07): : 603 - 616
  • [23] NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Harrison, Stephen A.
    Rinella, Mary E.
    Abdelmalek, Manal F.
    Trotter, James F.
    Paredes, Angelo H.
    Arnold, Hays L.
    Kugelmas, Marcelo
    Bashir, Mustafa R.
    Jaros, Mark J.
    Ling, Lei
    Rossi, Stephen J.
    DePaoli, Alex M.
    Loomba, Rohit
    LANCET, 2018, 391 (10126): : 1174 - 1185
  • [24] Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
    Stephen A. Harrison
    Federico Perez Manghi
    William B. Smith
    Diana Alpenidze
    Diego Aizenberg
    Naomi Klarenbeek
    Chi-Yi Chen
    Eli Zuckerman
    Eric Ravussin
    Phunchai Charatcharoenwitthaya
    Pin-Nan Cheng
    Helena Katchman
    Samuel Klein
    Ziv Ben-Ari
    Anisha E. Mendonza
    Yiming Zhang
    Miljen Martic
    Shenglin Ma
    Sheena Kao
    Sandra Tanner
    Alok Pachori
    Michael K. Badman
    YanLing He
    Chinweike Ukomadu
    Eric Sicard
    Nature Medicine, 2022, 28 : 1432 - 1438
  • [25] Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
    Harrison, Stephen A.
    Manghi, Federico Perez
    Smith, William B.
    Alpenidze, Diana
    Aizenberg, Diego
    Klarenbeek, Naomi
    Chen, Chi-Yi
    Zuckerman, Eli
    Ravussin, Eric
    Charatcharoenwitthaya, Phunchai
    Cheng, Pin-Nan
    Katchman, Helena
    Klein, Samuel
    Ben-Ari, Ziv
    Mendonza, Anisha E.
    Zhang, Yiming
    Martic, Miljen
    Ma, Shenglin
    Kao, Sheena
    Tanner, Sandra
    Pachori, Alok
    Badman, Michael K.
    He, YanLing
    Ukomadu, Chinweike
    Sicard, Eric
    NATURE MEDICINE, 2022, 28 (07) : 1432 - +
  • [26] A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
    Ciuleanu, T.
    Bazin, I.
    Lungulescu, D.
    Miron, L.
    Bondarenko, I.
    Deptala, A.
    Rodriguez-Torres, M.
    Giantonio, B.
    Fox, N. L.
    Wissel, P.
    Egger, J.
    Ding, M.
    Kalyani, R. N.
    Humphreys, R.
    Gribbin, M.
    Sun, W.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 680 - 687
  • [27] SEMAGLUTIDE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: SUBGROUP ANALYSIS OF A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 TRIAL
    Francque, Sven M.
    Kjaer, Mette Skalshoi
    Ladelund, Steen
    Okanoue, Takeshi
    Mateva, Lyudmila
    Shrestha, Ichhya
    Harrison, Stephen A.
    HEPATOLOGY, 2021, 74 : 1123A - 1124A
  • [28] Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis
    Sanyal, Arun
    Ling, Lei
    Neff, Guy
    Guy, Cynthia
    Bashir, Mustafa
    Paredes, Angelo
    Frias, Juan
    Younes, Ziad H.
    Trotter, James F.
    Gunn, Nadege T.
    Moussa, Sam
    Kohli, Anita
    Nelson, Kristen
    Gottwald, Mildred
    Chang, William
    Yan, Andrew
    DePaoli, Alex
    Lieu, Hsiao
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2021, 75 : S616 - S617
  • [29] Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
    Inoue, Takeshi
    Sasai, Kiyofumi
    Kitagawa, Tadayuki
    Nishimura, Akira
    Inada, Isao
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2020, 74 (02) : 140 - 148
  • [30] Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Harrison, Stephen A.
    Bashir, Mustafa R.
    Guy, Cynthia D.
    Zhou, Rong
    Moylan, Cynthia A.
    Frias, Juan P.
    Alkhouri, Naim
    Bansal, Meena B.
    Baum, Seth
    Neuschwander-Tetri, Brent A.
    Taub, Rebecca
    Moussa, Sam E.
    LANCET, 2019, 394 (10213): : 2012 - 2024
12345